ストックスクリーナーアプリを入手
2.18
1.40%
0.03
アフターアワーズ：
2.15
-0.03
-1.38%
前日終値:
$2.15
開ける：
$2.15
24時間の取引高:
1.17M
Relative Volume:
1.03
時価総額：
$154.06M
収益：
-
当期純損益:
$-192.96M
株価収益率:
-0.7786
EPS:
-2.8
ネットキャッシュフロー:
$-167.04M
1週間 パフォーマンス:
-8.79%
1か月 パフォーマンス:
+3.81%
6か月 パフォーマンス:
-55.05%
1年 パフォーマンス:
-86.01%
1日の値動き範囲:
$2.14
$2.20
1週間の範囲:
$2.10
$2.4302
52週間の値動き範囲:
$1.79
$15.80
Ventyx Biosciences Inc Stock (VTYX) Company Profile
名前
Ventyx Biosciences Inc
セクター
電話
(858) 945-2393
住所
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-03-21 | 開始されました | Wells Fargo | Overweight |
| 2022-12-19 | 開始されました | Goldman | Buy |
| 2022-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2022-09-07 | 開始されました | Stifel | Buy |
| 2022-09-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-09 | 開始されました | Credit Suisse | Outperform |
| 2022-03-31 | 開始されました | Canaccord Genuity | Buy |
| 2022-02-01 | 開始されました | Oppenheimer | Outperform |
| 2021-11-15 | 開始されました | Jefferies | Buy |
| 2021-11-15 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Ventyx Biosciences Inc (VTYX) 最新ニュース
Vanguard Group Inc's Strategic Acquisition in Ventyx Biosciences Inc - GuruFocus.com
Ventyx Biosciences: Ready To Escape "The Crash Cycle" (NASDAQ:VTYX) - Seeking Alpha
These 2 ‘Strong Buy’ Penny Stocks Could Rally Over 500%, Say Analysts - Markets Insider
Brokerages Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) PT at $8.29 - MarketBeat
HC Wainwright Cuts Earnings Estimates for Ventyx Biosciences - MarketBeat
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright - Investing.com
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 in Ulcerative Colitis at UEG Week 2024 - Marketscreener.com
Ventyx Biosciences maintains Neutral rating from H.C. Wainwright By Investing.com - Investing.com UK
Ventyx Biosciences Presents New 52-Week Results from the - GlobeNewswire
Ventyx Biosciences (NASDAQ:VTYX) Given "Neutral" Rating at HC Wainwright - MarketBeat
Ventyx reports positive Phase 2 ulcerative colitis trial data - Investing.com
Ventyx reports positive Phase 2 ulcerative colitis trial data By Investing.com - Investing.com Canada
VTYX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Ventyx Biosciences Inc (VTYX) stock analysis: A comprehensive overview - US Post News
Ventyx Biosciences Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024 - The Manila Times
Did Ventyx Biosciences Inc (VTYX) perform well in the last session? - US Post News
An analyst sees good growth prospects for Ventyx Biosciences Inc (VTYX) - SETE News
Sanofi Invests $27M in Ventyx Bio - San Diego Business Journal
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Ventyx Biosciences Inc (VTYX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Is Ventyx Biosciences Inc (VTYX) a good investment opportunity? - US Post News
Gaining Ground: Ventyx Biosciences Inc (VTYX) Closes Lower at 2.31, Down -2.12 - The Dwinnex
Take off with Ventyx Biosciences Inc (VTYX): Get ready for trading - SETE News
VTYX Stock Rises on Strategic Equity Investment Deal With SNY - MSN
Deerfield Management Company L.P. Series C Buys 2,287,570 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) - MarketBeat
Stock Surge: Ventyx Biosciences Inc (VTYX) Closes at 2.39, Marking a -2.85 Increase/Decrease - The Dwinnex
Ventyx Biosciences, Inc. (NASDAQ:VTYX) to Post FY2024 Earnings of ($2.13) Per Share, HC Wainwright Forecasts - MarketBeat
Sanofi’s $27 Million Investment in Ventyx Biosciences - Global Legal Chronicle
Adversity is less terrifying than hope: Ventyx Biosciences Inc (VTYX) - SETE News
Ventyx Biosciences retains stock target, neutral rating despite Sanofi's $27M stake - Investing.com
Benjamin F. Edwards & Company Inc. Buys 16,858 Shares of Twist Bioscience Co. (NASDAQ:TWST) - MarketBeat
Ventyx gets $27 million investment from Sanofi - The Pharma Letter
Ventyx deal a sign of Sanofi’s growing interest neuro-immunology? - BioCentury
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal - Pharmaceutical Technology
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences - MSN
Ventyx Biosciences Inc (VTYX) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Ventyx Biosciences (NASDAQ:VTYX) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
Ventyx stock climbs 8% on $27M Sanofi investment - MSN
Thoughtworks (NASDAQ:TWKS) Sees Large Volume Increase - Defense World
VTYX’s Q2 earnings predictions: What the experts say - US Post News
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright - TipRanks
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M - Fierce Biotech
Victory Capital (NASDAQ:VCTR) Hits New 12-Month High at $56.29 - MarketBeat
Ventyx stock climbs 8% on $27M Sanofi investment (NASDAQ:VTYX) - Seeking Alpha
Sanofi invests $27 million in Ventyx Biosciences By Investing.com - Investing.com India
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment - Marketscreener.com
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi - GlobeNewswire
(TWST) Pivots Trading Plans and Risk Controls - Stock Traders Daily
How the (TVE) price action is used to our Advantage - Stock Traders Daily
Seven Eight Capital LP Buys Shares of 22,269 Victory Capital Holdings, Inc. (NASDAQ:VCTR) - MarketBeat
Ventyx Biosciences Repeat Insider Selling Not A Positive Indicator - Simply Wall St
Ventyx Biosciences Inc (VTYX) 財務データ
収益
当期純利益
現金流量
EPS
Ventyx Biosciences Inc (VTYX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Krueger Christopher W | CHIEF BUSINESS OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,651 |
8,921 |
284,999 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,651 |
8,921 |
264,998 |
| Mohan Raju | CEO AND PRESIDENT |
Apr 02 '24 |
Sale |
5.40 |
4,312 |
23,299 |
1,578,250 |
| Auster Martin | CHIEF FINANCIAL OFFICER |
Apr 02 '24 |
Sale |
5.40 |
1,405 |
7,592 |
24,303 |
| Krueger Christopher W | CHIEF BUSINESS OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
286,650 |
| Auster Martin | CHIEF FINANCIAL OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
25,708 |
| Mohan Raju | CEO AND PRESIDENT |
Mar 28 '24 |
Option Exercise |
0.00 |
11,843 |
0 |
1,582,562 |
| Nuss John | CHIEF SCIENTIFIC OFFICER |
Mar 28 '24 |
Option Exercise |
0.00 |
4,531 |
0 |
266,649 |
| Nuss John | Chief Scientific Officer |
Dec 20 '23 |
Sale |
2.12 |
17,628 |
37,334 |
262,118 |
| Krueger Christopher W | Chief Business Officer |
Dec 20 '23 |
Sale |
2.12 |
5,293 |
11,210 |
282,119 |
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):